Scholarlink

<p>Inflammatory bowel disease (IBD) management remains a significant challenge due to its complex pathogenesis. While current therapies for IBD are effective in symptom management, a radical cure remains elusive. However, the high cost, adverse effects, and acquired drug resistance limit their long-term use, further highlighting the pressing need for safer, multifunctional, and precise therapeutic strategies. Herein, we developed a novel iron-based nanozyme (DHM-Fe) by coordinating dihydromyricetin (DHM) with iron ions. The DHM-Fe nanozyme confers antioxidant and anti-inflammatory effects by mimicking SOD/CAT activities and suppressing M1-like macrophage polarization. To improve gastric stability and targeting, the DHM-Fe nanozyme was encapsulated in yeast microcapsules (YM), forming the DF@YM oral delivery system. Oral administration of DF@YM exhibited good biocompatibility and alleviated DSS-induced colitis by suppressing pro-inflammatory responses, restoring barrier integrity, and modulating gut microbiota composition towards homeostasis. Metabolomic and molecular docking analyses revealed that DF@YM alleviates intestinal inflammation, potentially through activating the aryl hydrocarbon receptor (AhR)/IL22 pathway. Furthermore, direct visualization via mass spectrometry imaging confirmed that DF@YM markedly enhances the tissue-specific accumulation of DHM. As an oral delivery system for natural compounds, this multifunctional strategy enables precise targeting and synergistic regulation of the intestinal microenvironment, presenting a promising avenue for IBD treatment.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Self-adaptive nanozyme-loaded yeast microcapsules for multifunctional and precise therapy of colitis via intestinal microenvironment remodeling

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月11日

查看全文
  • Wen Yin,
  • Shuangjiao Hou,
  • Yaohui Ma,
  • Songyang Yao,
  • Jinwu Wei,
  • Dan Pu,
  • Xu Fu,
  • Dekui Zhang

摘要

Inflammatory bowel disease (IBD) management remains a significant challenge due to its complex pathogenesis. While current therapies for IBD are effective in symptom management, a radical cure remains elusive. However, the high cost, adverse effects, and acquired drug resistance limit their long-term use, further highlighting the pressing need for safer, multifunctional, and precise therapeutic strategies. Herein, we developed a novel iron-based nanozyme (DHM-Fe) by coordinating dihydromyricetin (DHM) with iron ions. The DHM-Fe nanozyme confers antioxidant and anti-inflammatory effects by mimicking SOD/CAT activities and suppressing M1-like macrophage polarization. To improve gastric stability and targeting, the DHM-Fe nanozyme was encapsulated in yeast microcapsules (YM), forming the DF@YM oral delivery system. Oral administration of DF@YM exhibited good biocompatibility and alleviated DSS-induced colitis by suppressing pro-inflammatory responses, restoring barrier integrity, and modulating gut microbiota composition towards homeostasis. Metabolomic and molecular docking analyses revealed that DF@YM alleviates intestinal inflammation, potentially through activating the aryl hydrocarbon receptor (AhR)/IL22 pathway. Furthermore, direct visualization via mass spectrometry imaging confirmed that DF@YM markedly enhances the tissue-specific accumulation of DHM. As an oral delivery system for natural compounds, this multifunctional strategy enables precise targeting and synergistic regulation of the intestinal microenvironment, presenting a promising avenue for IBD treatment.

Graphical Abstract